What is the recommended treatment for atopic dermatitis affecting the torso and neck skin?

Treatment of Atopic Dermatitis on Torso and Neck

For atopic dermatitis affecting the torso and neck, use medium-potency topical corticosteroids (TCS) as first-line therapy, with topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) reserved for the neck due to lower risk of skin atrophy in this sensitive area. 1

Anatomical Considerations for Treatment Selection

The neck requires special consideration compared to the torso because it is classified as a sensitive skin area with higher risk of steroid-induced atrophy, similar to the face and body folds 1. The torso can tolerate more potent therapies without the same atrophy concerns 1.

For the Torso

• Use medium-potency TCS (Class IV-V) as first-line treatment for active disease, which can be utilized for longer courses due to favorable adverse event profiles 1
• Apply once to twice daily until disease control is achieved 1
• High-potency steroids may be used initially for severe flares but should be limited to short courses due to atrophy risk 1
• Once controlled, transition to maintenance therapy with medium-potency TCS applied twice weekly (e.g., once daily for 2 days per week) to prevent relapses—this approach reduces relapse risk by 7-fold 1

For the Neck

• Prioritize lower-potency TCS or topical calcineurin inhibitors (TCIs) due to the neck being classified with face, genitals, and body folds as requiring lower potency agents 1
• Tacrolimus 0.1% ointment is strongly recommended with high certainty evidence for efficacy in atopic dermatitis, and it improved 5 of 7 outcomes in network meta-analysis 1, 2
• Pimecrolimus 1% cream is strongly recommended for mild-to-moderate disease with high certainty evidence, improving 6 of 7 outcomes and demonstrating significant itch reduction (RR: 2.09) 1, 2
• TCIs avoid the atrophy risk associated with long-term TCS use on the neck 3, 4

Comparative Efficacy Data

Recent network meta-analysis demonstrates that among topical treatments 2:

• Group 5 TCS (medium potency) were among the most effective for both acute treatment and maintenance, improving 6 outcomes
• Pimecrolimus improved 6 of 7 outcomes and was among the best performers for 2 outcomes
• Tacrolimus 0.1% improved 5 of 7 outcomes and was among the best for 2 outcomes
• These agents showed no increased harm compared to vehicle 2

Newer Topical Options

If first-line therapies fail or are not tolerated 5:

• Ruxolitinib cream (topical JAK1/JAK2 inhibitor) significantly improved disease severity with 4-fold improvement in treatment success at 8 weeks and comparable safety to vehicle 2, 6
• Tapinarof cream and roflumilast cream have strong recommendations for use in adults with atopic dermatitis 5

Practical Application Algorithm

1. Initial treatment phase:

   • Torso: Medium-potency TCS (Class IV-V) once to twice daily
   • Neck: Low-to-medium potency TCS OR tacrolimus 0.1%/pimecrolimus 1% twice daily
   • Continue until clear or nearly clear (typically 2-4 weeks) 1

2. Maintenance phase:

   • Apply medium-potency TCS twice weekly (e.g., 2 consecutive days per week) to previously affected areas 1
   • This reduces flare risk by 7-fold compared to emollients alone 1

3. Adjunctive therapy for all areas:

   • Daily emollients are essential for barrier repair 1, 7
   • Antihistamines for pruritus control 7, 4

Safety Considerations

The FDA black box warning on TCIs regarding cancer risk should not deter use, as long-term safety studies show the absolute risk of lymphoma is extremely low and not clinically meaningful 1. This makes TCIs particularly valuable for the neck where long-term TCS use carries definite atrophy risk 1, 3.

Common Pitfalls

• Avoid using high or very high potency TCS on the neck for extended periods—atrophy risk is substantially elevated in this area 1, 3
• Do not discontinue maintenance therapy once disease clears—twice-weekly TCS maintenance dramatically reduces relapse rates 1
• Head-and-neck dermatitis is often harder to treat than other body areas and negatively impacts quality of life more significantly, requiring persistent management 3